Agency Information Collection Activities: Proposed Collection; Comment Request, 51590-51591 [2019-21120]
Download as PDF
51590
Federal Register / Vol. 84, No. 189 / Monday, September 30, 2019 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Form name
Mother, ASD workflow Completed this study
step.
Clinic/Home Visit—Developmental Assessment(Attachment 7b, c, g), saliva collection (Attachment 8a–d), overall consent
(Attachment 15a).
Clinic/Home Visit—Saliva Collection (Attachments 8b–d).
Clinic/Home Visit—Developmental Assessment (attachment 7a, 7d or 7e or 7f) and
saliva collection (8a–d).
Invitation Packet/Response Card (Attachments 10c, 10f, and 10g).
Invitation Call Script (Attachment 11c) and
Social Communication Questionnaire (Attachment 3).
Enrollment Packet (Attachments 12a, c, d) ...
Father, ASD workflow Completed this study
step.
Child, ASD workflow Completed this study
step.
Mother, POP workflow All potential participants sent mailing.
Mother , POP workflow Potentially eligible
with contact by study staff.
Mother , POP workflow Eligible, consented,
and enrolled; assigned to the POP
workflow based on enrollment intake.
Mother, POP workflow Completed this study
step.
Mother,
step.
Mother,
step.
Mother,
step.
Mother,
step.
POP workflow Completed this study
POP workflow Completed this study
POP workflow Completed this study
POP workflow Completed this study
Father, POP workflow Completed this study
step.
Child, POP workflow Completed this study
step.
Mother, DD workflow All potential participants
sent mailing.
Mother, DD workflow Potentially eligible with
contact by study staff.
Mother, DD workflow Eligible, consented, and
enrolled; assigned to the DD workflow
based on enrollment intake.
Mother, DD workflow Completed this study
step.
Mother, DD workflow Completed this study
step.
Mother, DD workflow Completed this study
step.
Mother, DD workflow Completed this study
step.
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2019–21169 Filed 9–27–19; 8:45 am]
BILLING CODE 4163–18–P
khammond on DSKJM1Z7X2PROD with NOTICES
Number of
respondents
Type of respondents
1
225/60
164
1
15/60
328
1
135/60
1,466
1
10/60
733
1
30/60
334
1
20/60
301
1
15/60
301
1
1
267
1
105/60
267
1
20/60
234
1
50/60
117
1
15/60
234
1
90/60
641
1
10/60
321
1
30/60
175
1
20/60
Follow-up Phone Call Script (Attachment 13)
and Checklist and Pregnancy Reference
Form (Attachments 5a and 5b).
Maternal Interview Call (Attachment 4) .........
158
1
15/60
158
1
1
Self-Administered Forms (Attachments 6a–d,
6j, 6m, and 6o–p).
Follow-up Call 2 (Attachment 15b) ................
140
1
55/60
140
1
20/60
Follow-up Phone Call Script and Checklist
(Attachment 13) and Pregnancy Reference
Form Attachments 5a and 5b).
Maternal Interview Call (Attachment 4) .........
Self-Administered Forms (Attachment 6a–e,
6f or 6g, 6h–i, 6k, 6n–p).
Follow-up Call 2 (Attachment 14) ..................
Developmental Assessment saliva collection
(Attachment 8a–d), overall consent (Attachment 15c).
Clinic/Home Visit—Saliva Collection (Attachments 8b–d).
Clinic/Home Visit—Developmental Assessment Attachment 7a–c), saliva collection
(Attachment 8a–d).
Invitation Packet/Response Card (Attachments 10b, 10e, and 10g).
Invitation Call Script (Attachment 11b) and
SCQ (Attachment 3).
Enrollment Packet (Attachment 12b–d) .........
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10709]
Centers for Medicare &
Medicaid Services, HHS.
ACTION: Notice.
AGENCY:
19:16 Sep 27, 2019
Jkt 247001
Average
burden
per response
(in hours)
328
Agency Information Collection
Activities: Proposed Collection;
Comment Request
VerDate Sep<11>2014
Number of
responses per
respondent
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995 (the
PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
SUMMARY:
E:\FR\FM\30SEN1.SGM
30SEN1
Federal Register / Vol. 84, No. 189 / Monday, September 30, 2019 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
invited to send comments regarding our
burden estimates or any other aspect of
this collection of information, including
the necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions,
the accuracy of the estimated burden,
ways to enhance the quality, utility, and
clarity of the information to be
collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
November 29, 2019.
ADDRESSES: When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number l, Room C4–26–05,
7500 Security Boulevard, Baltimore,
Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, you may make your request
using one of following:
1. Access CMS’ website address at
website address at https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.html.
2. Email your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov.
3. Call the Reports Clearance Office at
(410) 786–1326.
FOR FURTHER INFORMATION CONTACT:
William N. Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the
use and burden associated with the
following information collections. More
detailed information can be found in
each collection’s supporting statement
and associated materials (see
ADDRESSES).
VerDate Sep<11>2014
19:16 Sep 27, 2019
Jkt 247001
CMS–10709 Hospital Survey for
Specified Covered Outpatient Drugs
(SCODs)
Under the PRA (44 U.S.C. 3501–
3520), federal agencies must obtain
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
The term ‘‘collection of information’’ is
defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA
requires federal agencies to publish a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, before
submitting the collection to OMB for
approval. To comply with this
requirement, CMS is publishing this
notice.
Information Collection
1. Type of Information Collection
Request: New collection (Request for a
new OMB control number); Title of
Information Collection: Hospital Survey
for Specified Covered Outpatient Drugs
(SCODs); Use: In the CY 2018 OPPS/
ASC payment system final rule with
comment period, CMS finalized a policy
to adjust payment for separately payable
outpatient drugs acquired by eligible
hospitals at discounted rates under
HRSA’s 340B program from Average
Sales Price (ASP) plus 6 percent to ASP
minus 22.5 percent. According to 42
U.S.C. 256b, eligible hospitals include
those with a Medicare Disproportionate
Share Hospital adjustment of greater
than 11.75 percent, Children’s
Hospitals, Critical Access Hospitals,
Cancer Hospitals, Rural Referral Centers
and Sole Community Hospitals. The
340B program sets a ceiling on the price
that covered entities pay for outpatient
drugs. The 340B ceiling price refers to
the maximum amount that a
manufacturer can charge a covered
entity for the purchase of a 340B
covered outpatient drug. The 340B
ceiling price is statutorily defined as the
Average Manufacturer Price (AMP)
reduced by the rebate percentage, which
is commonly referred to as the Unit
Rebate Amount (URA).
On December 27, 2018, the United
States District Court for the District of
Columbia ruled that the Secretary of the
Department of Health & Human Services
exceeded his statutory authority to
adjust payment rates under the Hospital
Outpatient Prospective Payment System
(OPPS) for separately payable, 340B-
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
51591
acquired drugs. See American Hospital
Ass’n v. Azar, 348 F. Supp. 3d 62, 82–
83 (D.D.C. 2018), appeal pending, Nos.
19–5048 & 19–5198 (D.C. Cir.). The
Court reasoned, in part, that the
Secretary had not collected the
necessary data to set payment rates
based on acquisition costs. The
government disagrees with that ruling
and has appealed. Nonetheless, in the
event that the ruling is affirmed, CMS
believes that it is important to begin
obtaining acquisition costs for specified
covered outpatient drugs to set payment
rates based on cost for 340B-acquired
drugs when they are furnished by
certain covered entity hospitals.
The acquisition cost data hospitals
submit in response to this survey will be
used to help determine payment
amounts for drugs acquired under the
340B program. We want to ensure that
the Medicare program pays for specified
covered outpatient drugs purchased
under the 340B program at amounts that
approximate what hospitals actually pay
to acquire the drugs. This will ensure
that the Medicare program uses taxpayer
dollars prudently while maintaining
beneficiary access to these drugs and
allowing beneficiary cost-sharing to be
based on the amounts hospitals actually
pay to acquire the drugs. Form Number:
CMS–10709 (OMB control number:
0938–New); Frequency: Occasionally;
Affected Public: Business or other forprofits and Not-for-profits, State, Local,
or Tribal Governments; Number of
Respondents: 761; Total Annual
Responses: 46,610,448; Total Annual
Hours: 33,484. (For policy questions
regarding this collection contact Steven
Johnson at 410–786–3332.)
Dated: September 25, 2019.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2019–21120 Filed 9–26–19; 4:15 pm]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3383–N]
Medicare, Medicaid, and CLIA
Programs; Clinical Laboratory
Improvement Amendments of 1988
Exemption of Laboratories Licensed
by the State of Washington
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
AGENCY:
E:\FR\FM\30SEN1.SGM
30SEN1
Agencies
[Federal Register Volume 84, Number 189 (Monday, September 30, 2019)]
[Notices]
[Pages 51590-51591]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-21120]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[Document Identifier: CMS-10709]
Agency Information Collection Activities: Proposed Collection;
Comment Request
AGENCY: Centers for Medicare & Medicaid Services, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Medicare & Medicaid Services (CMS) is
announcing an opportunity for the public to comment on CMS' intention
to collect information from the public. Under the Paperwork Reduction
Act of 1995 (the PRA), federal agencies are required to publish notice
in the Federal Register concerning each proposed collection of
information (including each proposed extension or reinstatement of an
existing collection of information) and to allow 60 days for public
comment on the proposed action. Interested persons are
[[Page 51591]]
invited to send comments regarding our burden estimates or any other
aspect of this collection of information, including the necessity and
utility of the proposed information collection for the proper
performance of the agency's functions, the accuracy of the estimated
burden, ways to enhance the quality, utility, and clarity of the
information to be collected, and the use of automated collection
techniques or other forms of information technology to minimize the
information collection burden.
DATES: Comments must be received by November 29, 2019.
ADDRESSES: When commenting, please reference the document identifier or
OMB control number. To be assured consideration, comments and
recommendations must be submitted in any one of the following ways:
1. Electronically. You may send your comments electronically to
https://www.regulations.gov. Follow the instructions for ``Comment or
Submission'' or ``More Search Options'' to find the information
collection document(s) that are accepting comments.
2. By regular mail. You may mail written comments to the following
address: CMS, Office of Strategic Operations and Regulatory Affairs,
Division of Regulations Development, Attention: Document Identifier/OMB
Control Number _, Room C4-26-05, 7500 Security Boulevard, Baltimore,
Maryland 21244-1850.
To obtain copies of a supporting statement and any related forms
for the proposed collection(s) summarized in this notice, you may make
your request using one of following:
1. Access CMS' website address at website address at https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing.html.
2. Email your request, including your address, phone number, OMB
number, and CMS document identifier, to [email protected].
3. Call the Reports Clearance Office at (410) 786-1326.
FOR FURTHER INFORMATION CONTACT: William N. Parham at (410) 786-4669.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the use and burden associated
with the following information collections. More detailed information
can be found in each collection's supporting statement and associated
materials (see ADDRESSES).
CMS-10709 Hospital Survey for Specified Covered Outpatient Drugs
(SCODs)
Under the PRA (44 U.S.C. 3501-3520), federal agencies must obtain
approval from the Office of Management and Budget (OMB) for each
collection of information they conduct or sponsor. The term
``collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA requires federal agencies
to publish a 60-day notice in the Federal Register concerning each
proposed collection of information, including each proposed extension
or reinstatement of an existing collection of information, before
submitting the collection to OMB for approval. To comply with this
requirement, CMS is publishing this notice.
Information Collection
1. Type of Information Collection Request: New collection (Request
for a new OMB control number); Title of Information Collection:
Hospital Survey for Specified Covered Outpatient Drugs (SCODs); Use: In
the CY 2018 OPPS/ASC payment system final rule with comment period, CMS
finalized a policy to adjust payment for separately payable outpatient
drugs acquired by eligible hospitals at discounted rates under HRSA's
340B program from Average Sales Price (ASP) plus 6 percent to ASP minus
22.5 percent. According to 42 U.S.C. 256b, eligible hospitals include
those with a Medicare Disproportionate Share Hospital adjustment of
greater than 11.75 percent, Children's Hospitals, Critical Access
Hospitals, Cancer Hospitals, Rural Referral Centers and Sole Community
Hospitals. The 340B program sets a ceiling on the price that covered
entities pay for outpatient drugs. The 340B ceiling price refers to the
maximum amount that a manufacturer can charge a covered entity for the
purchase of a 340B covered outpatient drug. The 340B ceiling price is
statutorily defined as the Average Manufacturer Price (AMP) reduced by
the rebate percentage, which is commonly referred to as the Unit Rebate
Amount (URA).
On December 27, 2018, the United States District Court for the
District of Columbia ruled that the Secretary of the Department of
Health & Human Services exceeded his statutory authority to adjust
payment rates under the Hospital Outpatient Prospective Payment System
(OPPS) for separately payable, 340B-acquired drugs. See American
Hospital Ass'n v. Azar, 348 F. Supp. 3d 62, 82-83 (D.D.C. 2018), appeal
pending, Nos. 19-5048 & 19-5198 (D.C. Cir.). The Court reasoned, in
part, that the Secretary had not collected the necessary data to set
payment rates based on acquisition costs. The government disagrees with
that ruling and has appealed. Nonetheless, in the event that the ruling
is affirmed, CMS believes that it is important to begin obtaining
acquisition costs for specified covered outpatient drugs to set payment
rates based on cost for 340B-acquired drugs when they are furnished by
certain covered entity hospitals.
The acquisition cost data hospitals submit in response to this
survey will be used to help determine payment amounts for drugs
acquired under the 340B program. We want to ensure that the Medicare
program pays for specified covered outpatient drugs purchased under the
340B program at amounts that approximate what hospitals actually pay to
acquire the drugs. This will ensure that the Medicare program uses
taxpayer dollars prudently while maintaining beneficiary access to
these drugs and allowing beneficiary cost-sharing to be based on the
amounts hospitals actually pay to acquire the drugs. Form Number: CMS-
10709 (OMB control number: 0938-New); Frequency: Occasionally; Affected
Public: Business or other for-profits and Not-for-profits, State,
Local, or Tribal Governments; Number of Respondents: 761; Total Annual
Responses: 46,610,448; Total Annual Hours: 33,484. (For policy
questions regarding this collection contact Steven Johnson at 410-786-
3332.)
Dated: September 25, 2019.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office of Strategic Operations and
Regulatory Affairs.
[FR Doc. 2019-21120 Filed 9-26-19; 4:15 pm]
BILLING CODE 4120-01-P